Department of Internal Medicine, An-Najah National University Hospital, Nablus, Palestine.
Sci Prog. 2024 Jul-Sep;107(3):368504241274023. doi: 10.1177/00368504241274023.
Serum albumin (ALB) plays a vital role in maintaining oncotic pressure and contributing to hemodynamic stability, with low levels associated with adverse outcomes in critically ill patients. This study aimed to assess the association between serum ALB concentrations and poor outcomes and the possible benefits of ALB supplementation.
A retrospective study involving 300 intensive care unit (ICU) patients. Albumin levels were recorded upon admission and throughout the stay, and patients were categorized based on a cutoff of 2.49 g/dl. The associations between low ALB levels and mortality were assessed using regression analysis. Additionally, it investigated the association of albumin supplementation with patient outcomes and mortality in specific patient populations.
The mean age was 54.9 years, with 68% having sepsis. Patients with low baseline ALB concentrations exhibited higher overall mortality (71% vs. 52%) and 28-day mortality (50% vs. 39%). Adjusted analyses confirmed associations with mortality. Albumin supplementation was administered to 53% of the patients. Its use demonstrated potential benefits, particularly in reducing mortality, when given to specific groups, such as sepsis and hypoalbuminemia patients.
The study confirms that low serum albumin levels are strongly associated with higher mortality rates in ICU patients. Albumin supplementation showed potential benefits, particularly in patients with sepsis and low albumin levels. Further analyses explored the dosage-response relationship and identified potential groups that would benefit from albumin supplementation.
Albumin can play a major role in predicting mortality in critically ill patients. Moreover, ALB supplementation may improve survival, especially in resource-limited settings. Future research should refine protocols through clinical trials for optimal survival in critically ill patients.
血清白蛋白（ALB）在维持胶体渗透压和维持血流动力学稳定方面发挥着重要作用，其水平低与危重症患者的不良结局相关。本研究旨在评估血清 ALB 浓度与不良结局的关系，以及 ALB 补充的可能益处。
一项纳入 300 例重症监护病房（ICU）患者的回顾性研究。入院时和住院期间记录白蛋白水平，并根据 2.49g/dl 的截断值对患者进行分类。使用回归分析评估低 ALB 水平与死亡率之间的关系。此外，还研究了白蛋白补充与特定患者人群的患者结局和死亡率之间的关系。
患者的平均年龄为 54.9 岁，68%有脓毒症。基线 ALB 浓度低的患者总死亡率（71%比 52%）和 28 天死亡率（50%比 39%）更高。调整分析证实了与死亡率的关联。53%的患者接受了白蛋白补充治疗。其使用在某些特定群体中显示出潜在的益处，特别是在降低死亡率方面，如脓毒症和低白蛋白血症患者。
本研究证实，血清白蛋白水平低与 ICU 患者的高死亡率密切相关。白蛋白补充显示出潜在的益处，特别是在脓毒症和低白蛋白血症患者中。进一步的分析探讨了剂量反应关系，并确定了可能受益于白蛋白补充的潜在人群。
白蛋白在预测危重症患者死亡率方面具有重要作用。此外，ALB 补充可能改善生存，尤其是在资源有限的情况下。未来的研究应通过临床试验来完善方案，以实现危重症患者的最佳生存。
